Colon-cancer screening cut the odds of dying from it by 43%

Data from a large European screening program indicate that people who actively took part in colorectal cancer screening had a 43 percent lower risk of dying from the disease than those who did not. The figure, drawn from long-term follow-up of a regional program, adds fresh weight to decades of evidence that catching the cancer early, or heading it off entirely, saves lives.

Colorectal cancer is one of the most common and deadly cancers worldwide, yet it is also among the most preventable, because screening can find and remove the growths that turn malignant before they ever become dangerous. The new numbers help quantify just how large that protective effect can be for people who follow through on screening.

The 43 percent figure explained

The estimate comes from the Stockholm–Gotland screening program, which followed participants for as long as 14 years. Researchers compared people who were invited to screening between 2008 and 2012 against a control group, and among those who actively participated, the risk of dying from colorectal cancer fell by 43 percent. As reporting on the analysis noted, the benefit was tied to actually taking part rather than merely being invited.

That distinction matters. Screening programs can only work if people accept the invitation, complete the test and follow up on abnormal results. The strong mortality reduction seen among active participants underscores how much the real-world payoff depends on uptake, not just on the availability of a test.

How screening prevents cancer deaths

Colorectal cancer usually develops slowly from precancerous growths called polyps, which can take years to progress into invasive disease. As the medical overview of the disease describes, screening works on two fronts: it can detect existing cancers at an early, more treatable stage, and it can find and remove polyps before they ever become cancerous. Removing a polyp during a colonoscopy prevents a cancer that might otherwise have formed.

This dual action is what makes colorectal cancer screening unusually powerful compared with screening for many other cancers. Rather than only catching disease early, it can stop the cancer from developing at all, which is why participation translates into fewer deaths over the long run. The slow pace at which the disease develops is precisely what gives screening its opening, since a growth that takes years to turn malignant offers many chances to be caught and removed. Early-stage colorectal cancer is also far more treatable than advanced disease, so even cases that are not prevented outright tend to be found when the odds of survival are much higher.

Stool tests, sigmoidoscopy and colonoscopy

Several screening methods exist, and they differ in how they are performed and how often they are needed. At-home stool tests look for hidden blood or altered DNA in a sample and can be done without a clinic visit, flagging people who then need a follow-up colonoscopy. Flexible sigmoidoscopy examines the lower portion of the colon with a scope, while colonoscopy inspects the entire length of the large intestine and allows polyps to be removed on the spot.

Long-term trials have reinforced the value of these approaches. A separate study that followed participants in Norway for 23 years found that a single flexible sigmoidoscopy was associated with a lower risk of developing colorectal cancer and of dying from it years later, illustrating that even a one-time screening can offer durable protection.

Who should be screened and when

Screening guidelines generally recommend that average-risk adults begin colorectal cancer screening in their mid-forties and continue at intervals that depend on the method used and the results. People with a family history of the disease, certain genetic conditions or inflammatory bowel disease may need to start earlier or be screened more often, decisions best worked through with a clinician.

The choice of test can itself improve participation. Because some people are reluctant to undergo a colonoscopy, offering a simple at-home stool test as a first step can draw in individuals who might otherwise skip screening entirely, with a colonoscopy reserved for those whose results warrant it.

Why participation is the deciding factor

The central lesson of the long-term data is that the benefit belongs to those who take part. A screening program can be well designed and widely offered, but its life-saving potential is realized only when people complete the tests and act on the findings. The 43 percent mortality reduction among active participants is a measure of what consistent engagement can achieve.

For public health systems, that points to a clear priority: making screening easy to access, reducing barriers such as cost and inconvenience, and encouraging people to follow through. Colorectal cancer remains a major cause of cancer death, but the evidence continues to show that a large share of those deaths could be avoided by screening that people actually complete.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview